FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 18282 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047. PMID 40940136 · J Immunother Cancer · 2025-Sep-12 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Long-Term Survival on Extent of Lymphadenectomy for Right-Sided Colon Cancer: Five-Year Follow-up Results of a Randomized Controlled Trial (RELARC Trial). PMID 40938728 · Ann Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of low- versus high-dose-LSD-assisted therapy in patients with major depression: A randomized trial. PMID 40482648 · Med · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy of natalizumab in secondary progressive multiple sclerosis: analysis of two phase III trials. PMID 40050011 · J Neurol Neurosurg Psychiatry · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. PMID 40015729 · J Neurol Neurosurg Psychiatry · 2025-Sep-12 未发现恶性肿瘤人群证据。 |
B
|
仅广召回影子组 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endovascular management of intracranial carotid blowout syndrome in patients with head and neck cancer. PMID 39237154 · J Neurointerv Surg · 2025-Sep-12 干预为非药物单独策略,未满足药物干预要求。 |
B
|
仅广召回影子组 | excludednon_drug_intervention | pending 0 Figure · 0 Panel · risk - |
| Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial. PMID 40935571 · BMJ · 2025-Sep-11 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 |
H
L
B
|
旧查询独有 | excludedsafety_or_economic_primary_endpoint | pending 0 Figure · 0 Panel · risk - |
| Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy. PMID 40888717 · N Engl J Med · 2025-Sep-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy. PMID 40888697 · N Engl J Med · 2025-Sep-11 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| US Food and Drug Administration Approval Summary: Trastuzumab Deruxtecan for the Treatment of Adult Patients With Hormone Receptor-Positive, Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2-Low or Human Epidermal Growth Factor Receptor 2-Ultralow Breast Cancer. PMID 40763319 · J Clin Oncol · 2025-Sep-10 The report meets criteria for oncology, human, randomized, time-to-event endpoint, drug intervention, and original result. However, the phase of the trial (Phase III/IIIb or Phase II/III) is not explicitly established in the provided metadata, making eligibility indeterminate. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Protocol: Faecal microbiota transfer in liver cancer to overcome resistance to atezolizumab/bevacizumab - a multicentre, randomised, placebo-controlled, double-blind phase II trial (the FLORA trial). PMID 40930564 · BMJ Open · 2025-Sep-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Using American Sign Language-Fluent Community Health Navigators to Advance Cancer Screening Adherence through Videoconferencing With Deaf, Deafblind, and Hard of Hearing Adults: Protocol for a Randomized Controlled Trial. PMID 40925603 · JMIR Res Protoc · 2025-Sep-09 The record is a protocol for a randomized controlled trial testing a non-drug intervention (ASL-fluent community health navigator) for cancer screening adherence, with primary/secondary outcomes being screening completion, communication, and knowledge. It does not present results from a Phase III/IIIb or Phase II/III randomized trial of a drug-containing intervention, and no time-to-event efficacy endpoint is specified. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| DigiNet: Optimizing personalized care for patients with stage IV non-small cell lung cancer (NSCLC) through a digitally connected provider network-analysis plan of a prospective multicenter cohort trial. PMID 40924208 · J Cancer Res Clin Oncol · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Subcutaneous versus intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated non-small cell lung cancer: Patient satisfaction and resource utilization results from the PALOMA-3 study. PMID 40730077 · Eur J Cancer · 2025-Sep-09 The record is from a relevant phase 3 oncology RCT with a drug intervention, but this specific publication reports secondary, non-efficacy outcomes (patient satisfaction, resource utilization) and does not present the formal results for a primary or key secondary time-to-event efficacy endpoint like OS or PFS. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of trifluridine/tipiracil plus bevacizumab on tumor shrinkage and depth of response in refractory metastatic colorectal cancer: analysis of the SUNLIGHT trial. PMID 40694985 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Patient-related prognostic factors in older adults with head and neck cancer: The EGeSOR clinical trial. PMID 40684734 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Response to letter to the editor on "Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76K trial". PMID 40680468 · Eur J Cancer · 2025-Sep-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients - A post-hoc analysis of the PETACC 8 trial. PMID 40680466 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Letter Re: Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial. PMID 40680465 · Eur J Cancer · 2025-Sep-09 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| The association between pretreatment emotional distress and response to tumor-infiltrating lymphocyte therapy in advanced melanoma. PMID 40674829 · Eur J Cancer · 2025-Sep-09 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Randomized clinical efficacy and safety study of peltopepimut-S plus cemiplimab compared to cemiplimab alone in patients with recurrent/metastatic HPV16-positive head and neck cancer. PMID 40921630 · J Immunother Cancer · 2025-Sep-08 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of upadacitinib maintenance therapy in patients with moderately to severely active Crohn's disease: 2-year results from the U-ENDURE Long-Term Extension study. PMID 40704669 · J Crohns Colitis · 2025-Sep-07 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Perampanel, Brivaracetam, Cenobamate, Stiripentol, and Ganaxolone in Lennox-Gastaut Syndrome: A Comprehensive Narrative Review. PMID 40944069 · J Clin Med · 2025-Sep-06 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Impact of Intraoperative Lidocaine During Oncologic Lung Resection on Long-Term Outcomes in Primary Lung Cancer: A Post Hoc Analysis of a Randomized Controlled Trial. PMID 40941021 · Cancers (Basel) · 2025-Sep-06 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Effective nutritional intervention improves the health-related quality of life (HRQL) of undernourished children with cancer: results of a randomized, controlled phase 3 trial. PMID 40913629 · Support Care Cancer · 2025-Sep-06 The study is an oncology Phase III randomized controlled trial in humans with a primary result report, but it is excluded because the intervention is non-drug (nutritional) and the endpoint is not time-to-event efficacy. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Choosing the best first-line therapy for extensive-stage small-cell lung cancer: anti-PD-1 or anti-PD-L1 inhibitors? PMID 40922293 · Medicine (Baltimore) · 2025-Sep-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Factors influencing locoregional recurrence rates in locally advanced rectal cancer after total neoadjuvant treatment versus chemoradiotherapy in the RAPIDO trial. PMID 41020329 · Br J Surg · 2025-Sep-02 The record is an original result report from a randomized Phase III trial (RAPIDO) in oncology with a drug intervention and a primary time-to-event endpoint (locoregional recurrence). Although the abstract focuses on subgroup analysis (sphincter-preserving vs. abdominoperineal resection), it reports results from the overall trial population and is not exclusively a post-hoc, biomarker, QoL, safety, or economic analysis. The abstract confirms the randomized, Phase III nature of the trial. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| A phase II trial of hepatic ablation of metastases to modulate and enhance immunotherapy response in non-small cell lung cancer (HAMMER-NSCLC). PMID 40898159 · BMC Cancer · 2025-Sep-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| CARBOMETASPINE: protocol for a multicenter, prospective, randomized controlled trial of carbonfiber spinal fixation in metastatic disease. PMID 40898139 · BMC Cancer · 2025-Sep-02 方案论文未报告临床试验结果。 |
B
|
仅广召回影子组 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES Trial. PMID 40847481 · J Am Heart Assoc · 2025-Sep-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Alteplase for Acute Ischemic Stroke at 4.5 to 24 Hours: The HOPE Randomized Clinical Trial. PMID 40773205 · JAMA · 2025-Sep-02 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Physical activity and mobility disability in older adult cancer survivors. PMID 40930715 · JNCI Cancer Spectr · 2025-Sep-01 The trial is a randomized clinical trial in older adults, but the intervention is a physical activity program, not a drug. While it includes cancer survivors as a subgroup, it is not a trial of a cancer treatment. Therefore, it does not meet the oncology drug intervention criterion. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Impact of temporary atezolizumab and bevacizumab interruption on survival in advanced HCC: an IMbrave150 analysis. PMID 40891895 · Oncologist · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| SGLT2i Dapagliflozin in primary prevention of chemotherapy induced cardiotoxicity in breast cancer patients treated with neo-adjuvant anthracycline-based chemotherapy +/- trastuzumab: rationale and design of the multicenter PROTECT trial. PMID 40890873 · Cardiooncology · 2025-Sep-01 The record describes the rationale and design of a randomized clinical trial but explicitly states it is ongoing with no results. It is a protocol report. Furthermore, the primary endpoint is cardiotoxicity incidence, which is not a time-to-event oncology efficacy endpoint (e.g., OS, PFS). Therefore, it is ineligible. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Optimizing bevacizumab dosing in first-line ovarian cancer treatment: the PGOG-ov1 trial. PMID 40890782 · Trials · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Optimizing short-term antibiotic treatment in patients with acute cholangitis: study protocol for an open-label randomized controlled trial (the BOLT-P3 trial). PMID 40890775 · Trials · 2025-Sep-01 方案论文未报告临床试验结果。 |
H
|
仅历史库存 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Effect of a self-made dietary therapy formula on the improvement of enteral feeding intolerance in patients with laryngeal cancer after surgery: A randomized controlled trial. PMID 40888947 · Support Care Cancer · 2025-Sep-01 The study is an oncology RCT with original results, but it is excluded because: (1) it does not have a primary/key secondary time-to-event efficacy endpoint (OS, PFS, etc.)—the primary outcomes are complications and nutritional parameters; (2) the intervention is a non-drug dietary formula, not a drug; (3) the trial phase is not specified, and there is no signal for Phase III/IIIb or Phase II/III. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer. PMID 40888443 · Endocr Relat Cancer · 2025-Sep-01 Study is an eligible Phase III randomized drug trial in oncology, but its primary endpoints are pathological response scores (PEPI, EPclin), not a pre-specified time-to-event efficacy endpoint (e.g., OS, PFS, DFS) or a Kaplan-Meier/HR analysis. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Managing, not lessening, uncertainty: a novel mind-body intervention for fear of cancer recurrence. PMID 40887510 · J Cancer Surviv · 2025-Sep-01 Excluded: Not a Phase III/IIIb or Phase II/III randomized trial; no drug intervention; primary/key endpoint is not time-to-event; intervention is non-drug psycho-oncology; report is secondary analysis of pilot study. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Physical fitness and clinically assessed disease burden in long-term childhood cancer survivors-The SURfit study. PMID 40831029 · Cancer · 2025-Sep-01 The study is a randomized trial in human cancer survivors, but it is not a Phase III trial with a drug intervention. The primary endpoint is disease burden (adverse health outcomes) and its association with physical fitness, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. The intervention is physical activity/exercise, not a drug. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Seladelpar: a comprehensive review of its clinical efficacy and safety in the treatment of primary biliary cholangitis. PMID 40773752 · J Basic Clin Physiol Pharmacol · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
|
仅历史库存 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Proportional Sedation for Persistent Agitated Delirium in Palliative Care: A Randomized Clinical Trial. PMID 40742738 · JAMA Oncol · 2025-Sep-01 The study is an oncology RCT with a drug intervention and original results, but it does not meet all required criteria: it is not a definitive Phase III trial, and its primary efficacy endpoint is not a time-to-event outcome (e.g., OS, PFS) but a continuous measure of agitation severity. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Tirzepatide Treatment and Associated Changes in β-Cell Function and Insulin Sensitivity in People With Obesity or Overweight With Prediabetes or Normoglycemia: A Post Hoc Analysis From the SURMOUNT-1 Trial. PMID 40694530 · Diabetes Care · 2025-Sep-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Behavioral Compared With Drug Therapy for Overactive Bladder Symptoms in Parkinson Disease: A Randomized Noninferiority Trial. PMID 40658410 · JAMA Neurol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: A Randomized Clinical Trial. PMID 40638104 · JAMA Oncol · 2025-Sep-01 The record meets most eligibility criteria (oncology, human, randomized, time-to-event endpoint, drug intervention, original result). However, it fails the explicit requirement for a Phase III/IIIb or Phase II/III trial, as the phase is not clearly stated in the provided metadata. Therefore, is_eligible is set to false. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of sacubitril/valsartan in Afro-descendant patients with resistant hypertension: a randomized controlled trial. PMID 40621831 · J Hypertens · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Expected vs observed effect sizes for survival endpoints in phase 3 oncology trials. PMID 40600894 · J Natl Cancer Inst · 2025-Sep-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Guselkumab for Moderate to Severe Psoriasis Across All Skin Tones: Cohort A of the VISIBLE Randomized Clinical Trial. PMID 40560559 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Guselkumab for Moderate to Severe Scalp Psoriasis Across All Skin Tones: Cohort B of the VISIBLE Randomized Clinical Trial. PMID 40560554 · JAMA Dermatol · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Benefit of Semaglutide in Symptomatic Peripheral Artery Disease by Baseline Type 2 Diabetes Characteristics: Insights From STRIDE, a Randomized, Placebo-Controlled, Double-Blind Trial. PMID 40543068 · Diabetes Care · 2025-Sep-01 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |